Halley E. Gilbert - 20 Nov 2025 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role: Director
Signature: /s/Latha Vairavan, as Attorney-in-Fact for Halley E. Gilbert
Issuer symbol: ARQT
Transactions as of: 20 Nov 2025
Net transactions value: -$363,670
Form type: 4
Filing time: 21 Nov 2025, 18:21:26 UTC
Previous filing: 16 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Gilbert Halley E	Director	C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE	/s/Latha Vairavan, as Attorney-in-Fact for Halley E. Gilbert	21 Nov 2025	0001601360

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ARQT	Common Stock	Options Exercise	$91,772	+12,220	+46%	$7.51	38,655	20 Nov 2025	Direct	F1
transaction	ARQT	Common Stock	Sale	$455,442	-16,532	-43%	$27.55	22,123	20 Nov 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ARQT	Stock Option (right to buy)	Options Exercise	$0	-12,220	-100%	$0.000000	0	20 Nov 2025	Common Stock	12,220	$7.51	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.
F2	The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $27.32 to $27.72, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Content

The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $27.32 to $27.72, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.